Ben Adams
About Ben Adams
Ben Adams is a reporter known for his coverage of significant developments in the biotechnology and pharmaceutical industries.
Ben Adams Reporter
Ben Adams is a reporter who specializes in covering significant developments in the field of gene therapy and immunotherapy. His work frequently includes in-depth articles on major pharmaceutical and biotech companies. Ben Adams has established himself as a reliable source of news and insights in these areas.
Article on Kyowa Kirin Buyout and Orchard FDA Approval
Ben Adams authored an article titled 'After Kyowa Kirin buyout, Orchard scores FDA approval for first MLD gene therapy in the US.' This article was published on March 18, 2024, at 3:25 pm. It covers the aftermath of Kyowa Kirin's acquisition and highlights Orchard's milestone FDA approval for their first metachromatic leukodystrophy (MLD) gene therapy in the United States.
Bluebird Bio Loan from Hercules Capital
Ben Adams wrote an article titled 'Bluebird bio secures loan lifeline from Hercules Capital to help support 3 gene therapy launches,' published on March 18, 2024, at 11:49 am. This piece details Bluebird Bio's financial maneuver to secure a loan from Hercules Capital, aiming to support the launch of three new gene therapies.
AstraZeneca and GSK Endometrial Cancer Immunotherapy
In another article published by Ben Adams, titled 'AstraZeneca, GSK make case for broad immunotherapy uses in endometrial cancer. But questions remain,' released on March 18, 2024, at 11:05 am, he discusses the efforts by AstraZeneca and GSK to advocate for the expanded use of immunotherapies in treating endometrial cancer. The article also addresses the ongoing questions and uncertainties within this area of treatment.